Cellumed Co

Cellumed Co Inventory

The Inventory of Cellumed Co (049180.KQ) as of Nov 19, 2026 is 6.94 B KRW. In the previous year, Inventory was 7.06 B KRW — a change of -1.66% (lower).

Inventory

6.94 BKRW

YoY

-1.66%

Last updated:

Inventory of Cellumed Co is 2025 6.94 B KRW. Inventory of Cellumed Co was 2024 7.06 B KRW. It decreases by -1.66% lower compared to the previous year.

The Cellumed Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
6.10 B KRW
Jan 1, 2019
3.19 B KRW
Jan 1, 2020
3.13 B KRW
Jan 1, 2021
5.50 B KRW
Jan 1, 2022
6.18 B KRW
Jan 1, 2023
7.76 B KRW
Jan 1, 2024
7.06 B KRW
Jan 1, 2025
6.94 B KRW
The Cellumed Co Inventory history
YEARInventoryYoY
6.94 BKRW-1.66%
7.06 BKRW-9.06%
7.76 BKRW+25.69%
6.18 BKRW+12.27%
5.50 BKRW+75.48%
3.13 BKRW-1.80%
3.19 BKRW-47.68%
6.10 BKRW-37.38%
9.74 BKRW-21.66%
12.44 BKRW-6.51%
13.31 BKRW-17.41%
16.11 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co Stock analysis

What does Cellumed Co do? Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care. Cellumed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellumed Co stock

Inventory of Cellumed Co is 6.94 B KRW in 2025.

Inventory of Cellumed Co changed from 7.06 B KRW to 6.94 B KRW, representing a -1.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory Cellumed Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Cellumed Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cellumed Co

All Key Metrics — Cellumed Co